Funding for this research was provided by:
Medizinische Universität Wien
Text and Data Mining valid from 2019-04-19
Received: 1 December 2018
Accepted: 27 March 2019
First Online: 19 April 2019
Compliance with ethical standards
: Hans-Jürgen Wester is shareholder of SCINTOMICS GmbH, Germany. SCINTOMICS owns the IP on Pentixafor.The other enlisted authors have no conflict of interest to declare.
: Our study reports two independent cohorts, which were analyzed independently, after receiving ethical permission from both ethical committees (Vienna and Peking).